MX2022001063A - Derivados de alcohol como abridores del canal de potasio kv7. - Google Patents
Derivados de alcohol como abridores del canal de potasio kv7.Info
- Publication number
- MX2022001063A MX2022001063A MX2022001063A MX2022001063A MX2022001063A MX 2022001063 A MX2022001063 A MX 2022001063A MX 2022001063 A MX2022001063 A MX 2022001063A MX 2022001063 A MX2022001063 A MX 2022001063A MX 2022001063 A MX2022001063 A MX 2022001063A
- Authority
- MX
- Mexico
- Prior art keywords
- potassium channel
- alcohol derivatives
- channel openers
- compounds
- potassium channels
- Prior art date
Links
- 229940127315 Potassium Channel Openers Drugs 0.000 title 1
- 150000001298 alcohols Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000004257 Potassium Channel Human genes 0.000 abstract 2
- 108020001213 potassium channel Proteins 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being saturated and containing rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
- C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19189750 | 2019-08-02 | ||
| CN201910734123 | 2019-08-09 | ||
| EP19191887 | 2019-08-15 | ||
| PCT/EP2020/071520 WO2021023617A1 (en) | 2019-08-02 | 2020-07-30 | Alcohol derivatives as kv7 potassium channel openers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022001063A true MX2022001063A (es) | 2022-02-14 |
Family
ID=71894829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022001063A MX2022001063A (es) | 2019-08-02 | 2020-07-30 | Derivados de alcohol como abridores del canal de potasio kv7. |
Country Status (27)
| Country | Link |
|---|---|
| EP (2) | EP4461725A3 (enExample) |
| JP (2) | JP7720829B2 (enExample) |
| KR (1) | KR102957984B1 (enExample) |
| CN (1) | CN114206830B (enExample) |
| AU (1) | AU2020325517B2 (enExample) |
| BR (1) | BR112021006324A2 (enExample) |
| CA (1) | CA3148719A1 (enExample) |
| CL (1) | CL2022000221A1 (enExample) |
| CO (1) | CO2022000080A2 (enExample) |
| CR (1) | CR20220028A (enExample) |
| DO (1) | DOP2022000026A (enExample) |
| EC (1) | ECSP22008993A (enExample) |
| ES (1) | ES2989376T3 (enExample) |
| GE (2) | GEAP202415862A (enExample) |
| HR (1) | HRP20241444T1 (enExample) |
| HU (1) | HUE069310T2 (enExample) |
| IL (1) | IL290193B2 (enExample) |
| JO (1) | JOP20220017A1 (enExample) |
| MA (1) | MA56708B1 (enExample) |
| MX (1) | MX2022001063A (enExample) |
| PE (1) | PE20220345A1 (enExample) |
| PH (1) | PH12022550192A1 (enExample) |
| PL (1) | PL4007634T3 (enExample) |
| RS (1) | RS66130B1 (enExample) |
| SM (1) | SMT202400445T1 (enExample) |
| WO (1) | WO2021023617A1 (enExample) |
| ZA (1) | ZA202109598B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2989376T3 (es) * | 2019-08-02 | 2024-11-26 | H Lundbeck As | Derivados de alcohol como abridores del canal de potasio Kv7 |
| AU2024310446A1 (en) * | 2023-06-27 | 2026-01-22 | Saniona A/S | Kv7 modulators |
| WO2026132415A1 (en) * | 2024-12-20 | 2026-06-25 | Saniona A/S | Kv7 modulators |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6893858B2 (en) | 2000-05-26 | 2005-05-17 | Bristol-Myers Squibb Company | Human kcnq5 potassium channel, methods and compositions thereof |
| WO2001096540A2 (en) | 2000-06-11 | 2001-12-20 | Dupont Pharmaceuticals Company | Hepatitis c protease exosite for inhibitor design |
| US7091202B2 (en) * | 2004-09-15 | 2006-08-15 | Bristol-Myers Squibb Company | 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators |
| US7790770B2 (en) * | 2005-11-23 | 2010-09-07 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| US20090118285A1 (en) | 2006-02-07 | 2009-05-07 | H. Lundbeck A/S | Use of kcnq-openers for treating or reducing the symptoms of schizophrenia |
| WO2007104717A1 (en) * | 2006-03-15 | 2007-09-20 | Neurosearch A/S | Quinazolinones and their use as potassium channels activators |
| CN101790374A (zh) | 2007-08-01 | 2010-07-28 | H.隆德贝克有限公司 | Kcnq钾通道开放剂用于减轻多巴胺能系统受到干扰的障碍或病症的症状或治疗这种障碍或病症的用途 |
| TW201024286A (en) * | 2008-11-27 | 2010-07-01 | Neurosearch As | Novel compounds |
| EP2928860A1 (en) * | 2012-12-10 | 2015-10-14 | H. Lundbeck A/S | New positive allosteric modulators of nicotinic acetylcholine receptor |
| WO2014145852A2 (en) * | 2013-03-15 | 2014-09-18 | Knopp Biosciences Llc | Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators |
| ES2749103T3 (es) * | 2014-09-12 | 2020-03-19 | Knopp Biosciences Llc | Benzoimidazol-1,2-ilamidas como activadores del canal Kv7 |
| JP2017095366A (ja) | 2015-11-18 | 2017-06-01 | 持田製薬株式会社 | 新規ビアリールアミド誘導体 |
| CN105663136A (zh) * | 2016-01-15 | 2016-06-15 | 河北中医学院 | 法舒地尔作为制备选择性Kv7离子通道激活剂药物的应用 |
| US10590067B2 (en) * | 2018-02-20 | 2020-03-17 | H. Lundbeck A/S | Alcohol derivatives of carboxamides as Kv7 potassium channel openers |
| ES3032221T3 (en) * | 2018-02-20 | 2025-07-16 | H Lundbeck As | Alcohol derivatives as kv7 potassium channel openers |
| ES2989376T3 (es) * | 2019-08-02 | 2024-11-26 | H Lundbeck As | Derivados de alcohol como abridores del canal de potasio Kv7 |
| US12508239B2 (en) * | 2019-08-02 | 2025-12-30 | H. Lundbeck A/S | Alcohol derivatives as Kv7 potassium channel openers for use in epilepsy or seizures |
-
2020
- 2020-07-30 ES ES20749879T patent/ES2989376T3/es active Active
- 2020-07-30 HU HUE20749879A patent/HUE069310T2/hu unknown
- 2020-07-30 IL IL290193A patent/IL290193B2/en unknown
- 2020-07-30 RS RS20241162A patent/RS66130B1/sr unknown
- 2020-07-30 EP EP24203380.1A patent/EP4461725A3/en active Pending
- 2020-07-30 PE PE2022000184A patent/PE20220345A1/es unknown
- 2020-07-30 PL PL20749879.1T patent/PL4007634T3/pl unknown
- 2020-07-30 MX MX2022001063A patent/MX2022001063A/es unknown
- 2020-07-30 CA CA3148719A patent/CA3148719A1/en active Pending
- 2020-07-30 CR CR20220028A patent/CR20220028A/es unknown
- 2020-07-30 WO PCT/EP2020/071520 patent/WO2021023617A1/en not_active Ceased
- 2020-07-30 EP EP20749879.1A patent/EP4007634B1/en active Active
- 2020-07-30 GE GEAP202415862A patent/GEAP202415862A/en unknown
- 2020-07-30 SM SM20240445T patent/SMT202400445T1/it unknown
- 2020-07-30 KR KR1020227002204A patent/KR102957984B1/ko active Active
- 2020-07-30 BR BR112021006324A patent/BR112021006324A2/pt unknown
- 2020-07-30 CN CN202080051950.0A patent/CN114206830B/zh active Active
- 2020-07-30 MA MA56708A patent/MA56708B1/fr unknown
- 2020-07-30 PH PH1/2022/550192A patent/PH12022550192A1/en unknown
- 2020-07-30 HR HRP20241444TT patent/HRP20241444T1/hr unknown
- 2020-07-30 AU AU2020325517A patent/AU2020325517B2/en active Active
- 2020-07-30 GE GEAP202015862A patent/GEP20247629B/en unknown
- 2020-07-30 JP JP2022505198A patent/JP7720829B2/ja active Active
-
2021
- 2021-11-25 ZA ZA2021/09598A patent/ZA202109598B/en unknown
-
2022
- 2022-01-11 CO CONC2022/0000080A patent/CO2022000080A2/es unknown
- 2022-01-25 JO JOP/2022/0017A patent/JOP20220017A1/ar unknown
- 2022-01-27 CL CL2022000221A patent/CL2022000221A1/es unknown
- 2022-02-02 DO DO2022000026A patent/DOP2022000026A/es unknown
- 2022-02-04 EC ECSENADI20228993A patent/ECSP22008993A/es unknown
-
2025
- 2025-07-03 JP JP2025112976A patent/JP7897992B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4241843A3 (en) | Alcohol derivatives as kv7 potassium channel openers | |
| PY1909256A (es) | Derivados de tetrahidroquinazolina útiles como agentes anticáncer | |
| ECSP20033467A (es) | Compuestos macrocíclicos para tratar enfermedades | |
| PY1906086A (es) | Derivados de quinazolina y piridopirimidina sustituidos útiles como agentes anticáncer | |
| ECSP19021312A (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad, kits, y métodos | |
| CL2022000221A1 (es) | Derivados de alcohol como abridores del canal de potasio kv7. | |
| CO2023006684A2 (es) | Anticuerpos contra sars-cov-2 y usos de los mismos | |
| CL2021001123A1 (es) | Derivados de arilsulfonilpirrolcarboxamida como activadores de canales de potasio kv3. | |
| CO2019012767A2 (es) | Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo | |
| CL2021001395A1 (es) | Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades. | |
| MX2018016273A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| MX2019015018A (es) | Composiciones que comprenden curones y usos de los mismos. | |
| CL2018001837A1 (es) | Compuestos antiproliferativos y sus composiciones farmacéuticas y usos | |
| NI201700055A (es) | 2-amino-6-(difluorometil)-5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| MX2022008479A (es) | Combinaciones de brimonidina de dosis baja y usos de las mismas. | |
| MX2022000781A (es) | Triterpenoides sintéticos heteroaromáticos sustituidos polarmente en c17, y métodos de uso de los mismos. | |
| MX2018000264A (es) | Formulaciones topicas de diacereina de rheina y sus usos. | |
| MX2021003888A (es) | Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares. | |
| ECSP22003596A (es) | Moduladores del receptor de nmda | |
| MX2021004647A (es) | Formas cristalinas de moduladores de los canales de potasio. | |
| UY38217A (es) | Derivados de 1-imidazotiadiazol-2h-pirrol-5-ona | |
| CO2021013311A2 (es) | Inhibidores del canal de potasio novedosos | |
| MX384767B (es) | Derivados de dihidrocalcona que influyen en estados inflamatorios. | |
| UY37316A (es) | Dispersión sólida farmacéutica de un inhibidor de bcl-2, composiciones farmacéuticas de ésta, y usos para el tratamiento de cáncer |